Role of Alzheimer's disease models in designing and testing experimental therapeutics

Alena V. Savonenko; Fiona M. Laird; Juan C. Troncoso; Philip C. Wong; Donald L. Price

doi:10.1016/j.ddmod.2005.11.006

Role of Alzheimer's disease models in designing and testing experimental therapeutics

Alena V. Savonenko, Fiona M. Laird, Juan C. Troncoso, Philip C. Wong, Donald L. Price

School of Medicine

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

The principal goals of investigating the models for Alzheimer's disease (AD) are to reproduce the amyloid/tau-related pathologies and the memory deficits occurring in patients. Recent models do allow crucial examinations of disease mechanisms and will be of great value in testing new therapeutic strategies including inhibition of BACE1 and β-secretase activities, modulators of γ-secretase and Aβ immunotherapies. Presently available mouse models can achieve a high degree of predictive validity for positive outcomes of experimental therapies, but they have been less successful in identifying potential adverse outcomes that can occur in human trials.

Original language	English (US)
Pages (from-to)	305-312
Number of pages	8
Journal	Drug Discovery Today: Disease Models
Volume	2
Issue number	4
DOIs	https://doi.org/10.1016/j.ddmod.2005.11.006
State	Published - 2005

ASJC Scopus subject areas

Molecular Medicine
Drug Discovery

Access to Document

10.1016/j.ddmod.2005.11.006

Cite this

@article{70ad999ef998480b91f3cfc223e469a1,

title = "Role of Alzheimer's disease models in designing and testing experimental therapeutics",

abstract = "The principal goals of investigating the models for Alzheimer's disease (AD) are to reproduce the amyloid/tau-related pathologies and the memory deficits occurring in patients. Recent models do allow crucial examinations of disease mechanisms and will be of great value in testing new therapeutic strategies including inhibition of BACE1 and β-secretase activities, modulators of γ-secretase and Aβ immunotherapies. Presently available mouse models can achieve a high degree of predictive validity for positive outcomes of experimental therapies, but they have been less successful in identifying potential adverse outcomes that can occur in human trials.",

author = "Savonenko, {Alena V.} and Laird, {Fiona M.} and Troncoso, {Juan C.} and Wong, {Philip C.} and Price, {Donald L.}",

year = "2005",

doi = "10.1016/j.ddmod.2005.11.006",

language = "English (US)",

volume = "2",

pages = "305--312",

journal = "Drug Discovery Today: Disease Models",

issn = "1740-6757",

publisher = "Elsevier Limited",

number = "4",

}

TY - JOUR

T1 - Role of Alzheimer's disease models in designing and testing experimental therapeutics

AU - Savonenko, Alena V.

AU - Laird, Fiona M.

AU - Troncoso, Juan C.

AU - Wong, Philip C.

AU - Price, Donald L.

PY - 2005

Y1 - 2005

N2 - The principal goals of investigating the models for Alzheimer's disease (AD) are to reproduce the amyloid/tau-related pathologies and the memory deficits occurring in patients. Recent models do allow crucial examinations of disease mechanisms and will be of great value in testing new therapeutic strategies including inhibition of BACE1 and β-secretase activities, modulators of γ-secretase and Aβ immunotherapies. Presently available mouse models can achieve a high degree of predictive validity for positive outcomes of experimental therapies, but they have been less successful in identifying potential adverse outcomes that can occur in human trials.

AB - The principal goals of investigating the models for Alzheimer's disease (AD) are to reproduce the amyloid/tau-related pathologies and the memory deficits occurring in patients. Recent models do allow crucial examinations of disease mechanisms and will be of great value in testing new therapeutic strategies including inhibition of BACE1 and β-secretase activities, modulators of γ-secretase and Aβ immunotherapies. Presently available mouse models can achieve a high degree of predictive validity for positive outcomes of experimental therapies, but they have been less successful in identifying potential adverse outcomes that can occur in human trials.

UR - http://www.scopus.com/inward/record.url?scp=30444441141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30444441141&partnerID=8YFLogxK

U2 - 10.1016/j.ddmod.2005.11.006

DO - 10.1016/j.ddmod.2005.11.006

M3 - Review article

AN - SCOPUS:30444441141

SN - 1740-6757

VL - 2

SP - 305

EP - 312

JO - Drug Discovery Today: Disease Models

JF - Drug Discovery Today: Disease Models

IS - 4

ER -

Role of Alzheimer's disease models in designing and testing experimental therapeutics

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this